RESULTS OF GLIOBLASTOMA PATIENTS TREATMENT AT 108 MILITARY CENTRAL HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the results of glioblastoma treatment at 108 Military Central Hospital. Subjects and methods: Retrospective descriptive study on 79 glioblastoma patients from 1/2018 to 12/2023, who underwent surgery, radiotherapy, and adjuvant chemotherapy. Results: In the study, 28/79 (35.4%) patients underwent gross total resection (GTR), 19% subtotal resection (STR), 34.2% partial resection (PR), and 11.4% biopsy. MGMT gene methylation status was detected in 12/33 (36.4%), 16/43 (37.2%) patients with IDH1 gene mutation. The median overall survival (OS) and progression-free survival (PFS) were 20 months and 15 months, respectively. At 1 year and 2 years, the OS rates were 84.5% and 36.2%, respectively, and the PFS rates were 60% and 19.5%. The median OS, PFS of the group of patients with MGMT methylation status was significantly higher than that of the group without MGMT methylation (OS 36 months and 16 months (p= 0.003), PFS 22 months and 12 months (p= 0.018)). The median OS of GTR/STR group was 24 months, and the group with PR/biopsy was 17 months (p= 0.012). PFS between these 2 groups was 17 months and 11 months, respectively (p= 0.023). The median OS of the group with RPA 3+4 and the group with RPA 5+6 was 21 months and 15 months (p=0.016). Grade 3+4 adverse events were only seen in 2 patients with increased GOT/GPT (2.5%), and 2 patients with grade 3+4 leukopenia and thrombocytopenia, the rest were mostly grade 1+2. Conclusion: The study showed that the surgical regimen combined with chemotherapy and radiotherapy is still the standard regimen, safe and well tolerated for GBM patients. The study also showed that MGMT methylation status, extent of tumor resection, and RPA had a significant impact on OS and PFS survival time.
Article Details
Keywords
Glioblastoma, GBM, MGMT methylation, RPA
References

2. Binabaj, M.M.; Bahrami, A.; et al. The Prognostic Value of MGMT Promoter Methylation in Glioblastoma: A Meta-Analysis of Clinical Trials. J. Cell. Physiol. 2018, 233, 378–386.

3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.

4. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142–8.

5. Roh et al. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. Medicine (2017) 96:27

6. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.

7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.

8. Salvatore Parisiet al. Temozolomide and Radiotherapy versus Radiotherapy Alone in High Grade Gliomas: A Very Long Term Comparative Study and Literature Review.

9. Szylberg, M.; Sokal, P, et al. MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study. Biomedicines 2022, 10, 2030.

10. Yuan, G.; Niu, L.; Zhang, Y.; et al. Defining Optimal Cutoff Value of MGMT Promoter Methylation by ROC Analysis for Clinical Setting in Glioblastoma Patients. J. Neurooncol. 2017, 133, 193–201. [CrossRef] [PubMed]
